Wellington Management Group LLP Acquires 18,019 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Wellington Management Group LLP grew its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 14.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 145,347 shares of the company's stock after purchasing an additional 18,019 shares during the period. Wellington Management Group LLP owned about 0.38% of Tarsus Pharmaceuticals worth $4,780,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Allspring Global Investments Holdings LLC increased its holdings in Tarsus Pharmaceuticals by 16.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company's stock worth $6,924,000 after buying an additional 29,465 shares during the last quarter. Creative Planning bought a new stake in Tarsus Pharmaceuticals during the third quarter worth approximately $362,000. Essex Investment Management Co. LLC bought a new position in Tarsus Pharmaceuticals in the third quarter worth $3,590,000. Vestal Point Capital LP bought a new position in Tarsus Pharmaceuticals in the third quarter worth $7,565,000. Finally, Assenagon Asset Management S.A. lifted its position in Tarsus Pharmaceuticals by 7.3% in the third quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company's stock worth $37,536,000 after purchasing an additional 77,825 shares during the period. Institutional investors and hedge funds own 90.01% of the company's stock.

Tarsus Pharmaceuticals Trading Up 3.0 %

Tarsus Pharmaceuticals stock traded up $1.53 during mid-day trading on Tuesday, hitting $53.26. The stock had a trading volume of 528,685 shares, compared to its average volume of 712,433. The stock has a 50-day simple moving average of $45.47 and a two-hundred day simple moving average of $34.64. The stock has a market capitalization of $2.04 billion, a PE ratio of -13.98 and a beta of 1.04. Tarsus Pharmaceuticals, Inc. has a 12 month low of $18.44 and a 12 month high of $54.44. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30.

Analyst Ratings Changes

Several research analysts recently commented on TARS shares. William Blair raised Tarsus Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 30th. The Goldman Sachs Group increased their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a research note on Friday, November 15th. Finally, Oppenheimer increased their price objective on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an "outperform" rating in a research note on Thursday, November 14th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $54.20.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.